Loading...
Loading...
NVO| Name | Value |
|---|---|
| Revenues | 71.3B |
| Cost of Revenue | 11.3B |
| Gross Profit | 60.0B |
| Operating Expense | 26.2B |
| Operating I/L | 33.8B |
| Other Income/Expense | 0.6B |
| Interest Income | 1.4B |
| Pretax | 34.4B |
| Income Tax Expense | 7.1B |
| Net Income/Loss | 27.3B |
Novo Nordisk A/S is a global healthcare company specializing in the research, development, manufacture, and marketing of pharmaceutical products. The company operates in two segments: Diabetes and Obesity care, and Biopharm. Its Diabetes and Obesity care segment offers a range of products including insulins, GLP-1 and related delivery systems, oral antidiabetic products, and treatments for obesity and other chronic diseases. The Biopharmaceuticals segment focuses on products for haemophilia, growth disorders, and hormone replacement therapy. Novo Nordisk A/S generates revenue through the sale of these pharmaceutical products and through collaboration agreements with other companies in the healthcare industry.
